Patient-centered methadone treatment: a randomized clinical trial

Area of Science:

• Addiction Medicine
• Clinical Psychology
• Public Health

Background:

• Opioid use disorder (OUD) treatment, particularly methadone, is crucial for preventing relapse.
• A significant number of patients discontinue methadone treatment within the first year, increasing relapse risk.
• Investigating novel treatment approaches is vital to improve patient outcomes in OUD management.

Purpose of the Study:

• To evaluate the effectiveness of a patient-centered methadone treatment (PCM) approach compared to treatment-as-usual (TAU).
• To determine if PCM improves participant outcomes at 12 months post-admission for opioid use disorder.

Main Methods:

• A two-arm, open-label randomized trial involving 300 newly admitted methadone patients.
• Patients were randomized to either PCM (optional counseling, modified counselor roles) or TAU.
• Primary outcome: opioid-positive urine test at 12-month follow-up; secondary outcomes included substance use, diagnostic criteria, risk behaviors, quality of life, and treatment retention.

Main Results:

• No significant difference in opioid-positive urine tests between PCM and TAU groups at 12 months (aOR=0.98, 95% CI=0.61-1.56).
• No significant differences observed in most secondary outcomes, including days of heroin/cocaine use and treatment retention (all P>0.05).
• A statistically significant improvement was noted in the Quality of Life Global Score for the PCM group (P=0.04).

Conclusions:

• Patient-centered methadone treatment, characterized by optional counseling and altered counselor responsibilities, did not demonstrate superior effectiveness over treatment-as-usual.
• The findings suggest that modifications in treatment structure, such as optional counseling, may not significantly impact key outcomes in methadone treatment for OUD.
• Further research may explore other patient-centered elements or different OUD populations to identify effective interventions.